Better Defining Growth Medium to Improve Reproducibility of Cell Culture (SBIR) (R43/R44 - Clinical Trial Not Allowed)
The summary for the Better Defining Growth Medium to Improve Reproducibility of Cell Culture (SBIR) (R43/R44 - Clinical Trial Not Allowed) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Better Defining Growth Medium to Improve Reproducibility of Cell Culture (SBIR) (R43/R44 - Clinical Trial Not Allowed): Fetal bovine serum (FBS) is the most widely used growth supplement for cell culture because it cost-effectively supports the survival and growth of many cell lines. Although serum is an effective growth promotor, it is highly variable in its composition, activity, and physiological effects on cells. This variability introduces inconsistencies into cell culture research. This Funding Opportunity Announcement (FOA) will support SBIR projects to develop novel, reliable, and cost-effective tools that will make it easier for researchers to standardize or replace serum in cell culture.
Federal Grant Title: | Better Defining Growth Medium to Improve Reproducibility of Cell Culture (SBIR) (R43/R44 - Clinical Trial Not Allowed) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PA-18-815 |
Type of Funding: | Grant |
CFDA Numbers: | 93.859 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | April 5th, 2021 |
Original Application Deadline: | April 5th, 2021 |
Posted Date: | June 5th, 2018 |
Creation Date: | June 5th, 2018 |
Archive Date: | May 11th, 2021 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | June 5th, 2018 |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PA-18-815.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Medical Scientist Training Program (MSTP) (T32)
- • Single Source: The NIGMS Human Genetic Cell Repository (U42 - Clinical Trial Not Allowed)
- • Native American Research Centers for Health (NARCH) Planning Grants (R34 - Clinical Trial ...
- • Modules for Enhancing Biomedical Research Workforce Training (R25 - Independent Clinical T...
- • Graduate Research Training Initiative for Student Enhancement (G-RISE) (T32)
- • Tools for Genetic and Genomic Studies in Emerging Model Organisms
- • Evolution of Infectious Diseases
- • Mbrs Support of Continuous Research Excellence (Score)
- More Grants from the National Institutes of Health
- • Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical ...
- • Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
- • Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
- • NINDS Program Project Grant (P01 Clinical Trial Optional)
- • Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial N...